Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency

checkorphan
Learn more about:
Ornithine Transcarbamylase Deficiency
Related Clinical Trial
Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn Hepatic Histopathology in Urea Cycle Disorders Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency Liver Disease in Urea Cycle Disorders Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With OTC Deficiency Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency Neurologic Injuries in Adults With Urea Cycle Disorders Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency

Brief Title

Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency

Brief Summary

      OBJECTIVES:

      I. Determine the safety, feasibility, and potential efficacy of intravascular adenoviral
      vector mediated gene transfer in the liver in adults with partial ornithine transcarbamylase
      deficiency.

Detailed Description

      PROTOCOL OUTLINE: This is a dose escalation study. Patients undergo a femoral arterial
      placement of a hepatic intraarterial catheter. Patients then receive adenoviral vector
      mediated gene transfer intravascularly over 30 minutes.

      Cohorts of 3 patients each receive escalating doses of adenoviral vector until the maximum
      tolerated dose is determined.

      Patients are followed at 3, 5, 7, 8, 15, and 29 days, at 2 months, and then every 3 months
      thereafter.

      Completion date provided represents the completion date of the grant per OOPD records

Study Phase

Phase 1

Study Type

Interventional

Condition

Ornithine Transcarbamylase Deficiency Disease

Intervention

Adenoviral Vector-Mediated Gene Transfer

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Genetic

Estimated Enrollment

21

Start Date

July 1998

Completion Date

September 2000

Eligibility Criteria

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Diagnosis of partial ornithine transcarbamylase deficiency Female heterozygote with
             abnormal allopurinol challenge or underlying defect in either N15 urea or N15
             glutamine OR Male with childhood/adulthood onset OR Family history of 2 affected
             children

          -  Stable for at least 1 month prior to study

          -  Plasma ammonium levels less than 50 micromoles

        --Prior/Concurrent Therapy--

          -  Concurrent alternate pathway therapy to control hyperammonemia allowed

        --Patient Characteristics--

          -  Hepatic: No history of liver disease

          -  Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use
             effective contraception No high level of neutralizing antibodies to the adenovirus

Gender

All

Ages

18 Years - 69 Years

Accepts Healthy Volunteers

No

Contacts

Steven E. Raper, ,

Administrative Informations

NCT ID

NCT00004498

Organization ID

199/14290

Secondary IDs

UPSM-FDR001529

Study Sponsor

University of Pennsylvania

Study Sponsor

Steven E. Raper, Study Chair, University of Pennsylvania

Verification Date

February 2000